Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
Extended interval dosing of natalizumab in multiple sclerosis.
Overview of the immune system.
Biogen Idec receives notification of PDUFA date extension
Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism.
Epigenetics of Multiple Sclerosis: An Updated Review.
The use of hematopoietic stem cells in autoimmune diseases.
Effects of Interferon β-1a and Interferon β-1b Monotherapies on Selected Serum Cytokines and Nitrite Levels in Patients with Relapsing-Remitting Multiple Sclerosis: A 3-Year Longitudinal Study.
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression.
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
Autoimmune sleep disorders.
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.
Effect of vitamin D on MS activity by disease-modifying therapy class.
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis.
[Flow cytometry model for the detection of neutralizing antibodies against of IFN-β].
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
Artesunate Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting Leukocyte Migration to the Central Nervous System.
Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction.
MicroRNAs: The Role in Autoimmune Inflammation.
Acorda Therapeutics announces Hatch-Waxman extension of AMPYRA® (dalfampridine) sustained-release formulation patent
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS).

Pages